Recombinant Human DCBLD2/ESDN Protein, CF Summary
Gln67-Ala528, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 300 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
DCBLD2 (discoidin, CUB, and LCCL domain containing protein 2), also known as CLCP1 and ESDN, is a 100-130 kDa glycoprotein that bears structural resemblance to the Neuropilin family of molecules. Mature human DCBLD2 is a type I transmembrane protein that consists of a 462 amino acid (aa) extracellular region (ECD), a 21 aa transmembrane segment, and a 226 aa cytoplasmic domain (1, 2). Within the ECD, human DCBLD2 shares approximately 88% aa sequence identity with mouse and rat DCBLD2. Alternative splicing generates an isoform that contains a 14 aa insertion in the cytoplasmic domain. DCBLD2 is expressed on vascular smooth muscle cells (VSMC), particularly in regions of arteriosclerosis and vascular injury (2, 3). It is up‑regulated on PDGF-BB stimulated VSMC and inhibits PDGF‑BB induced VSMC proliferation and migration (2‑4). It is also expressed on platelets and inhibits clot formation in a zebrafish model of thrombosis (5). Compared to normal tissue, DCBLD2 expression is down‑regulated in some gastric and neuroendocrine tumors but is up‑regulated in some metastatic lung cancers (1, 6, 7). It can be tyrosine phosphorylated in response to EGF R signaling and can inhibit colony formation and tumor cell invasiveness (6, 8, 9). Its direct association with Semaphorin 4B induces DCBLD2 degradation (10).
- Koshikawa, K. et al. (2002) Oncogene 21:2822.
- Kobuke, K. et al. (2001) J. Biol. Chem. 276:34105.
- Sadeghi, M.M. et al. (2007) Am. J. Transplant. 7:2098.
- Guo, X. et al. (2009) J. Biol. Chem. 284:29376.
- O’Connor, M.N. et al. (2009) Blood 113:4754.
- Kim, M. et al. (2008) Mol. Cancer Res. 6:222.
- Hofsli, E. et al. (2008) Br. J. Cancer 99:1330.
- Chen, Y. et al. (2007) Proteomics 7:2384.
- Orso, F. et al. (2008) FASEB J. 22:2702.
- Nagai, H. et al. (2007) Oncogene 26:4025.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human DCBLD2/ESDN Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human DCBLD2/ESDN Protein, CF and earn rewards!
Have you used Recombinant Human DCBLD2/ESDN Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image